Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2021 1
2022 1
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study.
Stacchiotti S, Baldi GG, Frezza AM, Morosi C, Greco FG, Collini P, Barisella M, Dagrada GP, Zaffaroni N, Pasquali S, Gronchi A, Huang P, Ingrosso M, Tinè G, Miceli R, Casali PG. Stacchiotti S, et al. Among authors: barisella m. Eur J Cancer. 2023 Dec;195:113391. doi: 10.1016/j.ejca.2023.113391. Epub 2023 Oct 18. Eur J Cancer. 2023. PMID: 37918286 Clinical Trial.
Fourteen patients were pre-treated, in 12 cases with antiangiogenics (median [m-] lines of treatment = 3). Sixteen patients were evaluable for response (one screening failure; one early discontinuation). ...Best RECIST responses were: 1/16 (6.2%) PR, 12/16 (75%) SD, 3/16 ( …
Fourteen patients were pre-treated, in 12 cases with antiangiogenics (median [m-] lines of treatment = 3). Sixteen patients were eval …
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression.
Stacchiotti S, Martini S, Pasquali S, Frezza AM, Beretta A, Percio S, Lecchi M, Tortoreto M, Barisella M, Collini P, Dagrada GP, Merlini A, Huang PH, Jenks A, Jones RL, Tap WD, Ingrosso M, Morosi C, Brich S, Giani C, Verderio P, Casali PG, Leonard H, Gronchi A, Zuco V, Zaffaroni N. Stacchiotti S, et al. Among authors: barisella m. Clin Cancer Res. 2024 Nov 15;30(22):5122-5137. doi: 10.1158/1078-0432.CCR-23-3991. Clin Cancer Res. 2024. PMID: 39283723 Free PMC article.
Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft.
Zuco V, Pasquali S, Tortoreto M, Percio S, Doldi V, Barisella M, Collini P, Dagrada GP, Brich S, Gasparini P, Fiore M, Casanova M, Frezza AM, Gronchi A, Stacchiotti S, Ferrari A, Zaffaroni N. Zuco V, et al. Among authors: barisella m. Dis Model Mech. 2023 Jun 1;16(6):dmm049649. doi: 10.1242/dmm.049649. Epub 2023 Jun 14. Dis Model Mech. 2023. PMID: 37158111 Free PMC article.
Irinotecan-based combinations nearly abrogated the expression of proteins of the G2/M checkpoint, preventing cell entrance in mitosis, and induced apoptotic and necroptotic cell death. Consistently, irinotecan plus trabectedin resulted in reprogramming of DSCRT transcripto …
Irinotecan-based combinations nearly abrogated the expression of proteins of the G2/M checkpoint, preventing cell entrance in mitosis …
Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
Zuco V, Pasquali S, Tortoreto M, Brich S, Percio S, Dagrada GP, Colombo C, Sanfilippo R, Lauricella C, Gounder M, El Bezawy R, Barisella M, Dei Tos AP, Casali PG, Gronchi A, Stacchiotti S, Zaffaroni N. Zuco V, et al. Among authors: barisella m. J Exp Clin Cancer Res. 2021 Mar 1;40(1):83. doi: 10.1186/s13046-021-01886-x. J Exp Clin Cancer Res. 2021. PMID: 33648535 Free PMC article.
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models.
Pantano F, Simonetti S, Iuliani M, Guillen MJ, Cuevas C, Aviles P, Cavaliere S, Napolitano A, Cortellini A, Mazzocca A, Nibid L, Sabarese G, Perrone G, Gambarotti M, Righi A, Palmerini E, Stacchiotti S, Barisella M, Gronchi A, Valeri S, Sbaraglia M, Dei Tos AP, Tonini G, Vincenzi B. Pantano F, et al. Among authors: barisella m. Oncogene. 2024 Sep;43(40):2986-2994. doi: 10.1038/s41388-024-03143-9. Epub 2024 Aug 28. Oncogene. 2024. PMID: 39198616 Free PMC article.
Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network.
Baldi GG, Lo Vullo S, Grignani G, Vincenzi B, Badalamenti G, Mastore M, Buonomenna C, Morosi C, Barisella M, Frezza AM, Provenzano S, Simeone N, Picozzi F, Mariani L, Casali PG, Stacchiotti S. Baldi GG, et al. Among authors: barisella m. Cancer. 2022 Apr 1;128(7):1439-1448. doi: 10.1002/cncr.34083. Epub 2022 Jan 13. Cancer. 2022. PMID: 35026050 Free article.
At a median follow-up of 54 months, the median OS (m-OS) was 30.3 months (interquartile range [IQR], 18.1-56.6), the m-PFS was 8.0 months (IQR, 5.1-17.0), the 6-month PFS rate was 65.2%, and the 12-month PFS rate was 30.3%. Of 22 patients who received wCDDP, the bes …
At a median follow-up of 54 months, the median OS (m-OS) was 30.3 months (interquartile range [IQR], 18.1-56.6), the m-PFS was …
Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft.
Stacchiotti S, Zuco V, Tortoreto M, Cominetti D, Frezza AM, Percio S, Indio V, Barisella M, Monti V, Brich S, Astolfi A, Colombo C, Pasquali S, Folini M, Gounder MM, Pantaleo MA, Collini P, Dei Tos AP, Casali PG, Gronchi A, Zaffaroni N. Stacchiotti S, et al. Among authors: barisella m. Cancers (Basel). 2019 Jul 19;11(7):1015. doi: 10.3390/cancers11071015. Cancers (Basel). 2019. PMID: 31331120 Free PMC article.
Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study.
Stacchiotti S, Simeone N, Lo Vullo S, Morosi C, Greco FG, Gronchi A, Barisella M, Collini P, Zaffaroni N, Dagrada GP, Frezza AM, Mariani L, Casali PG. Stacchiotti S, et al. Among authors: barisella m. Eur J Cancer. 2019 Jan;106:225-233. doi: 10.1016/j.ejca.2018.10.024. Epub 2018 Dec 5. Eur J Cancer. 2019. PMID: 30528807 Clinical Trial.
Pathologic diagnosis was centrally reviewed, distinguishing malignant SFT (M-SFT) and high-grade/dedifferentiated SFT (HG/D-SFT) subtypes. The primary end-point was the overall response rate (ORR) by Choi criteria (Choi). ...RESULTS: From April 2015 and October 2017, 17 el …
Pathologic diagnosis was centrally reviewed, distinguishing malignant SFT (M-SFT) and high-grade/dedifferentiated SFT (HG/D-SFT) subt …